KR20040047920A - 피페라진 우레아 유도체를 위한 고체 제약 제제 - Google Patents

피페라진 우레아 유도체를 위한 고체 제약 제제 Download PDF

Info

Publication number
KR20040047920A
KR20040047920A KR10-2004-7005591A KR20047005591A KR20040047920A KR 20040047920 A KR20040047920 A KR 20040047920A KR 20047005591 A KR20047005591 A KR 20047005591A KR 20040047920 A KR20040047920 A KR 20040047920A
Authority
KR
South Korea
Prior art keywords
methyl
pharmaceutical formulation
piperazine
solid pharmaceutical
ureido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7005591A
Other languages
English (en)
Korean (ko)
Inventor
헤이코 크란쯔
크리스토프 볼켈
랄프 립
요하네스 타크
허버트 비신거
Original Assignee
쉐링 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉐링 악티엔게젤샤프트 filed Critical 쉐링 악티엔게젤샤프트
Publication of KR20040047920A publication Critical patent/KR20040047920A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR10-2004-7005591A 2001-10-18 2002-10-07 피페라진 우레아 유도체를 위한 고체 제약 제제 Ceased KR20040047920A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10152351.3 2001-10-18
DE10152351A DE10152351B4 (de) 2001-10-18 2001-10-18 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
PCT/EP2002/011229 WO2003035037A1 (de) 2001-10-18 2002-10-07 Feste arzneimittelformulierung für ein piperazinharnstoffderivat

Publications (1)

Publication Number Publication Date
KR20040047920A true KR20040047920A (ko) 2004-06-05

Family

ID=7703496

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7005591A Ceased KR20040047920A (ko) 2001-10-18 2002-10-07 피페라진 우레아 유도체를 위한 고체 제약 제제

Country Status (23)

Country Link
EP (1) EP1435917A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005506365A (cg-RX-API-DMAC7.html)
KR (1) KR20040047920A (cg-RX-API-DMAC7.html)
CN (1) CN1571660A (cg-RX-API-DMAC7.html)
AR (1) AR037111A1 (cg-RX-API-DMAC7.html)
AU (1) AU2002333896B2 (cg-RX-API-DMAC7.html)
BR (1) BR0213340A (cg-RX-API-DMAC7.html)
CA (1) CA2463951A1 (cg-RX-API-DMAC7.html)
CO (1) CO5580740A2 (cg-RX-API-DMAC7.html)
DE (1) DE10152351B4 (cg-RX-API-DMAC7.html)
EC (1) ECSP045108A (cg-RX-API-DMAC7.html)
HR (1) HRP20040435A2 (cg-RX-API-DMAC7.html)
IL (1) IL161166A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04003522A (cg-RX-API-DMAC7.html)
NO (1) NO20042022L (cg-RX-API-DMAC7.html)
NZ (1) NZ532287A (cg-RX-API-DMAC7.html)
PE (1) PE20030472A1 (cg-RX-API-DMAC7.html)
PL (1) PL367987A1 (cg-RX-API-DMAC7.html)
RS (1) RS32204A (cg-RX-API-DMAC7.html)
RU (1) RU2311172C2 (cg-RX-API-DMAC7.html)
UY (1) UY27500A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003035037A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200403781B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101654582B1 (ko) 2016-05-12 2016-09-06 그린로드(주) 원뿔형 부유 고분자 필터, 및 그의 제조장치 및 제조방법, 및 그를 포함하는 수처리 필터

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3909056B2 (ja) 2001-06-27 2007-04-25 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
EP1749519A1 (de) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
AU2007242077B2 (en) * 2006-04-26 2013-11-14 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
RU2729223C1 (ru) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Дозированная форма для амплификации нуклеиновых кислот

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
ATE337307T1 (de) * 1998-02-05 2006-09-15 Pfizer Prod Inc Neue dihydroxyhexansäurederivate
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101654582B1 (ko) 2016-05-12 2016-09-06 그린로드(주) 원뿔형 부유 고분자 필터, 및 그의 제조장치 및 제조방법, 및 그를 포함하는 수처리 필터

Also Published As

Publication number Publication date
DE10152351B4 (de) 2005-09-22
CN1571660A (zh) 2005-01-26
MXPA04003522A (es) 2004-07-23
AU2002333896B2 (en) 2007-07-26
NO20042022L (no) 2004-05-14
AR037111A1 (es) 2004-10-20
PE20030472A1 (es) 2003-06-16
PL367987A1 (en) 2005-03-21
AU2002333896A2 (en) 2003-05-06
RU2004115328A (ru) 2005-06-10
EP1435917A1 (de) 2004-07-14
CA2463951A1 (en) 2003-05-01
HRP20040435A2 (en) 2005-06-30
RU2311172C2 (ru) 2007-11-27
BR0213340A (pt) 2004-10-05
JP2005506365A (ja) 2005-03-03
DE10152351A1 (de) 2003-05-08
WO2003035037A1 (de) 2003-05-01
UY27500A1 (es) 2003-06-30
NZ532287A (en) 2007-04-27
RS32204A (sr) 2006-10-27
CO5580740A2 (es) 2005-11-30
IL161166A0 (en) 2004-08-31
ECSP045108A (es) 2004-06-28
ZA200403781B (en) 2004-11-29

Similar Documents

Publication Publication Date Title
JP7627302B2 (ja) パルボシクリブの固形剤形
AU781881B2 (en) Cilostazol preparation
SK27099A3 (en) Tablet with controlled release of alfuzosine chlorhydrate
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
JPH0122245B2 (cg-RX-API-DMAC7.html)
JPH09511767A (ja) 新規な経口用の医薬使用形態
JPH07558B2 (ja) モピダモール製剤
JPH0251402B2 (cg-RX-API-DMAC7.html)
JP2004501099A (ja) アルドステロン頂点位相時の放出のためのアルドステロンアンタゴニスト組成物
EP1737432A2 (en) Orally disintegrating tablets and methods of manufacture
CA2761212A1 (en) Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of it manufacturing
JP2005533774A (ja) ジバルプロエクスソジウムの放出遅延剤
JP4022269B2 (ja) 医薬組成物
MXPA02008059A (es) Formulaciones en multiparticulas biomoduladas.
JP2004532258A (ja) 薬剤組成物
AU2002333896B2 (en) Solid pharmaceutical formulation for a piperazine urea derivative
CZ287149B6 (en) Pharmaceutical preparation containing gemfibrozil
JP4263776B2 (ja) イブジラストの徐放化経口錠剤およびその製造方法
JP3929522B2 (ja) 難水溶性薬物の徐放性製剤
WO2005082329A2 (en) Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
US20030087913A1 (en) Solid pharmaceutical agent formulation for a piperazine urea derivative
CN100420437C (zh) 磷酸川芎嗪缓释微丸及制备方法
KR20230088399A (ko) 듀테트라베나진을 포함하는 위체류성 제형
WO2013111147A1 (en) Extended release compositions of nevirapine

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040416

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20071008

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090508

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090715

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090508

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I